Can-Fite BioPharma (NYSE:CANF – Get Free Report) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.
Separately, EF Hutton Acquisition Co. I raised shares of Can-Fite BioPharma to a “strong-buy” rating in a research note on Wednesday, July 17th.
Check Out Our Latest Stock Analysis on Can-Fite BioPharma
Can-Fite BioPharma Stock Performance
Institutional Inflows and Outflows
An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC grew its stake in Can-Fite BioPharma Ltd. (NYSE:CANF – Free Report) by 35.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by institutional investors and hedge funds.
Can-Fite BioPharma Company Profile
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.
Featured Articles
- Five stocks we like better than Can-Fite BioPharma
- There Are Different Types of Stock To Invest In
- Chinese Stocks Cool Off: Time to Buy the Dip in These 2 Stocks?
- Using the MarketBeat Dividend Yield Calculator
- Goldman Sachs Highlights 3 Top Short Squeeze Stocks to Watch
- How to Calculate Inflation Rate
- Walmart is Up 56% YTD, Is it Still a Top Consumer Staples Stock?
Receive News & Ratings for Can-Fite BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Can-Fite BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.